Loading menu...
Prostate cancer is the second leading cause of cancer deaths among US men  Over 200,000 new patients are diagnosed with prostate cancer every year in the US alone  About 35,000 of these men have advanced metatstatic prostate tumor for whom there is no cure 

Colby Pharmaceutical Company is engaged in discovery and development of novel small molecule drugs targeting prostate cancer. read more »

 
 

Colby drugs have activity against mid-stage recurrent and late-stage metastatic prostate cancer in animal model

Colby has identified four Oxidative Stress Modulator (OSM) drug candidates for treatment of prostate cancer, each targeting and modulating a different oxidative stress promoting various different cellular  metabolic pathways.
 
With access to data from over $15 million in grants from NCI, DOD and other government and private instututions, Colby has demonstrated prostate cancer remission and significantly longer survival time in animal models.  read more »
 

OSM-ChemGen, Oxidative Stress-Chemical Genomics Platform for small molecule OSM drug discovery and development 

OSM-ChemGen Platform is a powerful chemistry and genomics driven drug discovery and development technology identifying multiple genetic pathways involved in therapy of prostate and other diseases. read more»
 

Disclaimer and Forward-Looking Statements

This web site contains "forward-looking statements," including statements about the Company's growth, future operating results, discovery and development of products, strategic alliances and intellectual property.Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events, future revenues or performance, capital expenditures, compensation arrangements, financing needs, plans or intentions relating to acquisitions, business trends and other information that is not historical information. Various important risks may cause the Company's actual results to differ materially from the results indicated by these forward-looking statements, including: adverse results in its drug discovery, pre-clinical and clinical development programs; failure to obtain grants; failure to obtain patent protection for its discoveries; commercial limitations imposed by patents owned or controlled by third parties; difficulties or delays in obtaining regulatory approvals to market products and services resulting from the Company's development efforts; product withdrawals; competitive factors; difficulties or delays in commercialization of Company's products; and the requirement for substantial funding to conduct research and development and to expand commercialization activities.

 

Highlights


 

Upcomming Events:

03.25.08 David Zarling, PhD, MBA will speak at CHI Molecular Medicine Tri-Conference Pharma/BioTech Alliance 

 

Recent Events:

03.17.08   Colby's Chief Scientific Officer, Hirak Basu, PhD,  has been selected for presentation at the 2008 Midwest Venture Capital Summit, Chicago, IL.  

02.22.08   David Zarling, PhD, MBA presented two talks at GTCbio 5th Cancer Drugs R&D conference in Phoenix, Arizona

 

   

Meet Colby Executives